- Home
- NML vs MGTX Comparison
NML vs MGTX Comparison
Compare NML & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- MGTX
- Stock Information
- Founded
- NML 2012
- MGTX 2015
- Country
- NML United States
- MGTX United States
- Employees
- NML N/A
- MGTX N/A
- Industry
- NML Finance/Investors Services
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NML Finance
- MGTX Health Care
- Exchange
- NML Nasdaq
- MGTX Nasdaq
- Market Cap
- NML 500.9M
- MGTX 520.8M
- IPO Year
- NML N/A
- MGTX N/A
- Fundamental
- Price
- NML $8.78
- MGTX $8.47
- Analyst Decision
- NML
- MGTX Strong Buy
- Analyst Count
- NML 0
- MGTX 2
- Target Price
- NML N/A
- MGTX $24.00
- AVG Volume (30 Days)
- NML 219.3K
- MGTX 547.7K
- Earning Date
- NML 01-01-0001
- MGTX 08-11-2025
- Dividend Yield
- NML 9.75%
- MGTX N/A
- EPS Growth
- NML N/A
- MGTX N/A
- EPS
- NML N/A
- MGTX N/A
- Revenue
- NML N/A
- MGTX $34,508,000.00
- Revenue This Year
- NML N/A
- MGTX $365.04
- Revenue Next Year
- NML N/A
- MGTX $73.18
- P/E Ratio
- NML N/A
- MGTX N/A
- Revenue Growth
- NML N/A
- MGTX 203.23
- 52 Week Low
- NML $6.09
- MGTX $3.85
- 52 Week High
- NML $7.33
- MGTX $8.75
- Technical
- Relative Strength Index (RSI)
- NML 49.74
- MGTX 76.43
- Support Level
- NML $8.71
- MGTX $6.31
- Resistance Level
- NML $8.89
- MGTX $8.75
- Average True Range (ATR)
- NML 0.13
- MGTX 0.45
- MACD
- NML -0.02
- MGTX 0.19
- Stochastic Oscillator
- NML 35.29
- MGTX 89.55
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.